Search | IOVS | ARVO Journals

iovs

Issues
Topics
For Authors
About
- Editorial Board

Journals Home

MANAGE ALERTS

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

To View More...

Purchase this article with an account.

or

Subscribe Now

Issues
Topics
For Authors
About
- Editorial Board

Narrow View

NARROW

Content Type

Meeting Abstract (11)
Journal Articles (1)

Journal

Investigative Ophthalmology & Visual Science (12)

Article Type

ARVO Annual Meeting Abstract (11)
Retina (1)

Topics

Eye Anatomy and Disorders (1)
Genetics (1)
Retina (1)

Tags

angiogenesis (1)
bevacizumab (1)
choroidal neovascularization (1)
chronic exertional compartment syndrome (1)
in situ nick-end labeling (1)
oxidation-reduction (1)
stat3 protein (1)

Specify Date Range

From: To: Apply

Showing 1 – 12 of 12

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Ref-1 inhibitor APX2009 regulates hypoxia signaling in murine subretinal neovascularization and human retinal endothelial cells

Anbukkarasi Muniyandi; Eyram K. Kpenu; Gabriella Hartman; Mark R Kelley; Timothy William Corson

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2165.

ARVO Annual Meeting Abstract June 2024

Ref-1 redox activity modulates canonical Wnt signaling in human retinal endothelial cells

Gabriella Hartman; Eyram K. Kpenu; Mijit Maihemuti; Mark R Kelley; Timothy William Corson

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4580.

ARVO Annual Meeting Abstract June 2023

ZETA-1 Phase 2 Trial to Determine the Safety and Efficacy of APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

Daniel Su; Jay Stuart Pepose; Mark R Kelley; Audrey Lazar; Louis Haddad; Mina Sooch; Mitchell G Brigell; Peter K Kaiser; David S Boyer

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3753.

ARVO Annual Meeting Abstract June 2023

Ref-1 inhibitor APX2009 is antiangiogenic in murine choroidal neovascularization and human choroidal endothelial cells

Anbukkarasi Muniyandi; Kamakshi Sishtla; Gabriella Hartman; Yang Song; Andi R Masters; Sara K Quinney; Mark R Kelley; Timothy William Corson

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):935.

ARVO Annual Meeting Abstract June 2023

Ref-1 is overexpressed in murine retinal neovascularization and localizes with nuclei of multiple retinal cell types

Gabriella Hartman; Anbukkarasi Muniyandi; Mark R Kelley; Timothy William Corson

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1249.

ARVO Annual Meeting Abstract June 2022

APE1/Ref-1 is overexpressed and colocalizes with neovascular tufts and hypoxic regions in the oxygen-induced retinopathy mouse model

Gabriella D Hartman; Anbukkarasi Muniyandi; Mark R Kelley; Timothy William Corson

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):269 – F0314.

ARVO Annual Meeting Abstract June 2022

APE1/Ref-1 is highly expressed in murine laser-induced choroidal neovascularization and human neovascular age-related macular degeneration

Anbukkarasi Muniyandi; Gabriella D Hartman; Kristina Day; Xiaoping Qi; Michael Boulton; Mark R Kelley; Timothy William Corson

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):0005.

ARVO Annual Meeting Abstract June 2022

The safety of APX3330, an oral drug candidate for the treatment of diabetic eye disease, in the ongoing masked 24-week ZETA-1 Phase 2 clinical trial

David S Boyer; Mitch Brigell; Ajay Kolli; Kavon Rahmani; Audrey Lazar; Mina Sooch; Ronil Patel; Eliot Lazar; Jay Stuart Pepose; Mark R Kelley

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):675 – F0129.

ARVO Annual Meeting Abstract June 2021

Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling

Larissa Lachi Silva; Nathan Lambert-Cheatham; Robert E Stratford; Sara Kay Quinney; Timothy William Corson; Mark R. Kelley

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1073.

Retina July 2014

Suppression of Choroidal Neovascularization Through Inhibition of APE1/Ref-1 Redox Activity

PDF

Yue Li; Xiuli Liu; Tongrong Zhou; Mark R. Kelley; Paul A. Edwards; Hua Gao; Xiaoxi Qiao
TAGS: choroidal neovascularization, oxidation-reduction, angiogenesis, bevacizumab, in situ nick-end labeling, chronic exertional compartment syndrome, stat3 protein
Invest. Ophthalmol. Vis. Sci.. 2014; 55(7):4461-4469. https://doi.org/10.1167/iovs.14-14451

ARVO Annual Meeting Abstract March 2012

Regulation of Retinal Vascular Permeability by Inhibition of APE1/Ref-1 Redox Activity with APX3330

Yue Li; Xiuli Liu; Tongrong Zhou; Mark R. Kelley; Paul Edwards; Hua Gao; Xiaoxi Qiao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5558.

ARVO Annual Meeting Abstract March 2012

Selective Blocking of APE1/Ref-1 Redox Function by a Novel Compound, APX3330 Inhibits Choroidal Endothelial Cells in vitro and Choroidal Neovascularization in vivo

Xiaoxi Qiao; Yue Li; Tongrong Zhou; Xiuli Liu; Mark R. Kelley; Paul Edwards; Hua Gao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5559.

« Previous

Advertisement

Follow @ARVOiovs

IOVS Home
Issues
Topics
For Authors
About
- Editorial Board

Online ISSN: 1552-5783

Investigative Ophthalmology & Visual Science
Journal of Vision
Translational Vision Science & Technology

JOURNALS HOME
TOPICS
ABOUT ARVO JOURNALS

Copyright © 2025 Association for Research in Vision and Ophthalmology.

Access Provided By:
MIT Libraries

Forgot password?

To View More...

Purchase this article with an account.

Create an Account

or

Subscribe Now

×

×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept